论文信息 - BMS bets on targeting IL-8 to enhance cancer immunotherapies - 字舞流文

BMS bets on targeting IL-8 to enhance cancer immunotherapies

[1] A. Biankin,et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma , 2016, Cancer cell.

[2] C. Sheridan. Immune-checkpoint inhibitors march on, now in combinations , 2014, Nature Biotechnology.

[3] Malorye Allison. Bristol-Myers Squibb swallows last of antibody pioneers , 2009, Nature Biotechnology.

[4] C. Dinney,et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5] B. Mian,et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. , 2002, The American journal of pathology.